This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Robbins Umeda LLP Announces The Filing Of A Securities Fraud Class Action Lawsuit Against Abiomed, Inc.





SAN DIEGO and DANVERS, Mass., Nov. 27, 2012 /PRNewswire/ -- Shareholder rights firm Robbins Umeda LLP announces that a complaint has been filed in the United States District Court for the District of Massachusetts on behalf of persons who purchased Abiomed, Inc. (NASDAQ: ABMD) ("Abiomed" or the "Company") stock between August 5, 2011 and October 31, 2012 (the "Class Period"), alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its officers and directors.

(Logo: http://photos.prnewswire.com/prnh/20111014/ROBBINSUMEDALOGO)

Abiomed manufactures, markets, and sells various types of medical devices designed for circulatory support and continuum of care in heart recovery to acute heart failure patients. Throughout the Class Period, the Company's principle product was the Impella 2.5 Cardiac Support System ("Impella 2.5"). The complaint alleges that, throughout the Class Period, Abiomed issued a series of materially false and misleading statements to investors about the Company's financial strength and prospects.  Specifically, the complaint alleges that positive statements regarding the Company were materially false and misleading because the FDA repeatedly warned Abiomed that the Company's marketing and promotional materials regarding the Impella 2.5 contained inappropriate claims and suggested improper off-label uses. Abiomed repeatedly assured investors that the FDA's concerns had been addressed and that the matter was resolved.

Then, on November 1, 2012, Abiomed announced that the United States Department of Justice was investigating "the Company's marketing and labeling of the Impella 2.5." On this news, Abiomed's share price fell 32%, from $19.82 per share on October 31, 2012 to close at $13.61 on November 1, 2012.

If you purchased or otherwise acquired Abiomed stock during the Class Period and wish to serve as lead plaintiff, you must act no later than January 15, 2013.  To discuss your shareholder rights, please contact attorney Darnell R. Donahue at (800) 350-6003, inquiry@robbinsumeda.com, or via the shareholder information form on the firm's website. 

Robbins Umeda LLP is a nationally recognized leader in securities litigation and shareholder rights law.  The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested.  For more information, please go to http://www.robbinsumeda.com.  

Press release link: http://www.robbinsumeda.com/shareholders-rights-blog/abiomed-inc/.

Attorney Advertising. Past results do not guarantee a similar outcome.  

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs